Respiratory Syncytial Virus

Discussion in 'Stocks' started by nursebee, Aug 15, 2014.

  1. nursebee

    nursebee

    This shit is fun to watch.
     
    #81     Jul 9, 2015
  2. nursebee

    nursebee



    Get your rocks off!
     
    #82     Jul 9, 2015
  3. nursebee

    nursebee

    I've revisited my comp analysis for NVAX based upon current figures for ALXN and JAZZ (Aug 14 first page this topic) and maintain future price possibilities of $164-369.

    Institutional ownership last reported as 65.23%

    Those poor Canslimmers gonna miss the bulk of this move
     
    #83     Jul 14, 2015
  4. nursebee

    nursebee

    THoughts: We have retraced back to the previous breakout/consolidation area, perhaps safe to add or go long. But the pattern is quite broken, needs time to develop.

    They put out Ebola stage 1 data and three more trials yet to come.
    Insider selling or bad data could void any trades at this point.
     
    #84     Jul 27, 2015
  5. nursebee

    nursebee

    As a former chart monkey, the potential of the action is interesting. hammer.PNG
     
    #85     Jul 27, 2015
  6. nursebee

    nursebee

  7. nursebee

    nursebee

    Almost a year ago this thread was started.
    If anyone took a trade near the start, triple your money.
     
    #87     Aug 11, 2015
  8. nursebee

    nursebee

  9. Hello nursebee:

    These biotechs are hard to fathom some work and some don't. NVAX if you go back in time you will find me pushing it very hard right here at Elite Trader. Recently though I think it's been that annoying Jim Crammer talking it up.

    Novavax (NVAX - Get Report): In an exclusive interview, Cramer sat down with Stanley Erck, president and CEO of Novavax, the vaccine maker that's roared 120% since Nursebee featured the company in mid-January.

    Erck explained that drug companies have been working on vaccines for viruses like Respiratory Syncytial Virus, or RSV, for over 50 years, but Novavax took a new approach to engineering a nano-particle that invokes a powerful immune response in the body that it showing promising results. RSV affects mainly babies, children and the elderly, Erck noted, and is a big issue.

    Novavax is also working on vaccines for pandemic flu. ////

    --> Call me old fashioned nursebee but I think these new cancer vax's are too risky. They want my kid to get some HPV type vax something we never got as young adults-- I'm not going to allow it if I can get in the Dr's ear.

    As for me, I am petrified of cancer, everyone is getting it and dying. Dr's want to look around and find stuff it's a fine line because sometimes if you wait until you have symptoms it's too late... I know that, it's a risk but I just don't like Dr's. They never give you good news. Just a bill. They killed my father (botched VA operation 1965) and breast cancer took my mother.

    The Health System is broken. Obama Care is a disgrace. I have had my insurance cancelled now three years running it just happened again with aetna. I'm considering a Health savings account as no one in my family goes to the Dr anyway. Sign up. can't get your Dr or your son's Dr so these devilish HMO's try and force some scrub Dr on you-- Like that will ever happen in my family- I will never be pushed into seeing a certain Dr the same way I will never be forced onto a particular flight-- choices should be made from the comfort of one's home.

    Anyway pandemic flu?

    I much prefer little INO. INNOVO, of course it's a dog and I'm down on it but I think they are going eventually to make it. The three I originally bought together for the same reasons ( I believe at the time it was Bird Flue! ) NVAX, BCRX, INO. ~stoney
     
    #89     Aug 17, 2015
  10. Crammer sniffed around INO a bit too but has not pushed it:

    Inovio Pharmaceuticals
    (INO - Get Report): In his second interview segment, Cramer sat down with Dr. J. Joseph Kim, president and CEO of Inovio, a stock that's roared up 26% over the past two days on the news of a partnership with AstraZeneca (AZN) that could yield up to $700 million in milestone payments for the company.

    Kim explained that Inovio's immunotherapy platform generates T-cells in the body that act as "Navy Seals" to seek out and eliminate cancer cells in the body. What makes their platform unique is Inovio's platform can target specific types of cancers better than anyone else.

    Kim continued by noting that the same synthetic DNA technology can also be applied to everything from Hepatitis-C and HIV to influenza and Ebola.///////
     
    #90     Aug 17, 2015